.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

AAM Access!

Biosimilars CEOs: Opportunities Abound, but Regulatory, “Branding” Hurdles Remain

February 24th 2022

Article

There remains risk in the US market due to regulatory and legal hurdles—not to mention a combative political environment, according to executives who gathered last week during the “CEOs Unplugged” session at Access! 2022, held by the Association for Accessible Medicines (AAM) in Orlando.

CMS Seeks Answers for Slower-Than-Expected Biosimilar Adoption, Rawal Says

February 21st 2022

Article

Purva Rawal, PhD, senior advisor and chief strategy officer, Center for Medicare and Medicaid Innovation, spoke during the Association for Accessible Medicines' Access! annual meeting, which gathered in Orlando, Florida, February 15-16.

Experts Call for More Regulatory Action to Address Biosimilar Interchangeability Confusion

February 17th 2022

Article

A panel of experts details the current concerns regarding interchangeability designations for biosimilars in the United States and calls for regulators and policy makers to make changes to allow to easier access to biosimilars and greater adoption.